The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Landscape analysis of urothelial carcinoma (UC) by telomerase reverse transcriptase (TERT) alterations.
 
Tyler F. Stewart
Consulting or Advisory Role - Seattle Genetics/Astellas
Research Funding - GRAIL
 
Magalie Dosset
No Relationships to Disclose
 
Pavel Brodskiy
Employment - Caris Life Sciences
 
Joanne Xiu
Employment - Caris Life Sciences
 
Arash Rezazadeh
Stock and Other Ownership Interests - ECOM Medical
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; EMD Serono; Exelixis; Genentech; Gilead Sciences; Immunomedics; Novartis; Pfizer
Speakers' Bureau - Amgen; Astellas Medivation; AstraZeneca; AVEO; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Exelixis; Genentech/Roche; Gilead Sciences; Gilead Sciences; Janssen; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi; Seattle Genetics/Astellas; Seattle Genetics/Astellas
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bavarian Nordic (Inst); Bayer (Inst); BeyondSpring Pharmaceuticals (Inst); BioClin Therapeutics (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); Epizyme (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Janssen (Inst); Macrogenics (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Astellas Medivation; AstraZeneca; Bayer; Eisai; Exelixis; Genentech; Janssen; Novartis; Pfizer; Prometheus
 
Nataliya Mar
Speakers' Bureau - Astellas Pharma; Seagen
 
Sourat Darabi
Honoraria - OncoLens
Consulting or Advisory Role - Bayer
 
Michael J. Demeure
Consulting or Advisory Role - Bayer; Loxo/Lilly; OnCusp Therapeutics; Orphagen Pharmaceuticals; Pfizer; TD2; Theralink
(OPTIONAL) Uncompensated Relationships - transmed7
 
Pedro C. Barata
Consulting or Advisory Role - Bayer; BMS; Caris Life Sciences; Clovis Oncology (Inst); Dendreon (Inst); Eisai; EMD Serono; Pfizer
Speakers' Bureau - Bayer (Inst); Caris Life Sciences (Inst); Pfizer/Astellas (Inst)
Research Funding - AVEO (Inst); Blue Earth Diagnostics (Inst); Merck (Inst); Pfizer (Inst)
 
Daniel M. Geynisman
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Exelixis; Merck; Myovant Sciences; Pfizer; Seattle Genetics/Astellas
Research Funding - Astellas Pharma (Inst); Calithera Biosciences (Inst); Genentech (Inst); Harpoon therapeutics (Inst); Merck (Inst)
 
Pooja Ghatalia
Research Funding - AstraZeneca (Inst); Bristol Myers Squibb Foundation (Inst); Merck (Inst)
 
Monika Joshi
Consulting or Advisory Role - Seagen
Research Funding - AstraZeneca (Inst); Eisai (Inst); Pfizer (Inst)
 
Chethan Ramamurthy
Consulting or Advisory Role - Seagen
Speakers' Bureau - Gilead Sciences
 
Chadi Nabhan
Employment - Caris Life Sciences
Leadership - Caris Life Sciences
Stock and Other Ownership Interests - Caris Life Sciences
 
Elisabeth I. Heath
Honoraria - Bayer; Sanofi; Seagen
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Sanofi
Speakers' Bureau - Sanofi
Research Funding - Agensys (Inst); AIQ Solutions (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calibr (Inst); Caris Life Sciences (Inst); Celgene (Inst); Celldex (Inst); Champions Oncology (Inst); Corcept Therapeutics (Inst); Curemeta (Inst); Daiichi Sankyo Inc. (Inst); Dendreon (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); Esanik (Inst); Five Prime Therapeutics (Inst); Fortis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Infinity Pharmaceuticals (Inst); Inovio Pharmaceuticals (Inst); Janssen Research & Development (Inst); Medivation (Inst); Merck (Inst); Merck Sharp & Dohme (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Modra Pharmaceuticals (Inst); Novartis (Inst); Oncolys BioPharma (Inst); Pellficure (Inst); Peloton Therapeutics (Inst); Pharmacyclics (Inst); Plexxikon (Inst); Seagen (Inst); Synta (Inst); Tokai Pharmaceuticals (Inst); Zenith Epigenetics (Inst); Zenith Epigenetics (Inst)
Other Relationship - Caris Centers of Excellence
 
Hannah Carter
Stock and Other Ownership Interests - ClearPoint Neuro, Inc. (I)
 
Maurizio Zanetti
Leadership - Invectys
Stock and Other Ownership Interests - Invectys
Consulting or Advisory Role - Invectys
 
Rana R. McKay
Consulting or Advisory Role - Astellas Medivation; AstraZeneca; AVEO; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Caris Life Sciences; Dendreon; Exelixis; Janssen; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi; Sorrento Therapeutics; Tempus; Vividion Therapeutics
Research Funding - Bayer (Inst); Pfizer (Inst); Tempus (Inst)